Advertisement

Topics

Latest "Cerus" News Stories

18:44 EDT 23rd October 2017 | BioPortfolio

Here are the most relevant search results for "Cerus" found in our extensive news archives from over 250 global news sources.

More Information about Cerus on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cerus for you to read. Along with our medical data and news we also list Cerus Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cerus Companies for you to search.

Showing "Cerus" News Articles 1–25 of 34

Monday 23rd October 2017

Cerus Announces National German Reimbursement for Pathogen Inactivated Platelets

Cerus Corporation (NASDAQ:CERS) announced today that the Institute for the Hospital Remuneration System (Institut für das Entgeltsystem im Krankenhaus, or InEK) in Germany will include pathogen-inactivated platelets for national reimbursement starting January 1, 2018. Pathogen-inactivated platelets will be reimbursed through ZE (Zusatzentgelte) codes 164 ...


Thursday 19th October 2017

Cerus to Release Third Quarter 2017 Results on November 2, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Thursday, November 2, 2017, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company’s financial results and provide a general business overview and ...

Tuesday 10th October 2017

Global Infectious Disease Diagnostics Market Forecast 2017-2027

LONDON, October 10, 2017 /PRNewswire/ -- Revenue Prospects by Disease Type (HIV/AIDS, Hepatitis, Tuberculosis, Malaria, Chlamydia), Technique (Immunoassay, Molecular Diagnostics, POC/Rapid Diagnosis, Microbiology), End User (Hospitals, Clinical Laboratories, Others) and Geography Infectious Disease Diagnostics - our new study reveals trends, R&D progress, and predicted revenues: ...


Thursday 5th October 2017

Cerus Announces First Biologics License Application Approval for U.S. Blood Center Customer

Approval allows interstate shipment of INTERCEPT Platelets Cerus Corporation (NASDAQ:CERS) announced today that Rhode Island Blood Center received approval by the U.S. Food and Drug Administration (FDA) on their Biologics License Application (BLA) requesting allowance for interstate distribution of platelets that have been pathogen-reduced with the INT...

Monday 2nd October 2017

Cerus Announces Schedule of Presentations at the 2017 AABB Annual Meeting

Cerus Corporation (NASDAQ:CERS) announced today its schedule of key events at the AABB (formerly known as the American Association of Blood Banks) Annual Meeting to be held October 7-10 in San Diego, California. Cerus will be presenting the latest clinical data while blood banks and hospitals will be publishing results from their own user experience. ...

Thursday 28th September 2017

Cerus (CERS) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

Wednesday 20th September 2017

Cerus to Present at Cantor Fitzgerald’s Annual Healthcare Conference on September 27, 2017

Cerus Corporation (NASDAQ:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 10:20 AM ET on Wednesday, September 27, 2017. A live webcast of the presentation will be available from the Investor Relations ...

Monday 18th September 2017

POC Diagnostics Market Forecast 2017-2027

LONDON, September 18, 2017 /PRNewswire/ -- Revenue Prospects by Product (Blood Glucose, Infectious Diseases, Rapid Coagulation, Rapid Cardiac Marker, Cholesterol, Pregnancy, Other) and Major National Markets with an Assessment of Leading Companies POC Diagnostics - our new study reveals trends, R&D progress, and predicted revenues:       (Logo: http://mma....

Monday 11th September 2017

Cerus Corporation (CERS) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow

Thursday 7th September 2017

Cerus Endovascular Provides Corporate Update

FREMONT, Calif. and OXFORD, England, Sept. 7, 2017 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneur...

Wednesday 30th August 2017

Cerus to Present at Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, will present at two upcoming conferences: Baird’s 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel in New York City on September 6, 2017 at 9:40 AM ET. BioCentu...

Tuesday 29th August 2017

Today's Research Report Coverage on Biotech Stocks -- Bellicum Pharma, Cara Therapeutics, Cerus, and Coherus Biosciences

NEW YORK, August 29, 2017 /PRNewswire/ -- If you want a Stock Review on BLCM, CARA, CERS, or CHRS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. This morning, DailyStockTracker.com revisits the Biotech space, which consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. Th...

Tuesday 22nd August 2017

Is Cerus's Intercept A Pick-6?

Monday 7th August 2017

Cerus Corp CERS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25072017] Prices from USD $250

SummaryCerus Corp Cerus is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusiontransmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for...

Sunday 6th August 2017

Cerus' (CERS) CEO Obi Greenman on Q2 2017 Results - Earnings Call Transcript

Thursday 3rd August 2017

Cerus Reports Second Quarter 2017 Results

  Life Sciences Jobs   ...

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2017. Recent developments include: Expanded INTERCEPT Blood Systems supply agreement with Établissement Français du Sang (EFS), the French National blood service, supporting INTERCEPT platelet production in potentially a...

Oxford Finance provides $40M amended credit facility to Cerus

Cyrus secured an amended growth capital credit facility worth $40 million from Oxford Finance.  -More- 

Wednesday 2nd August 2017

Cerus Enters Into $40 Million Amended Growth Capital Agreement

New loan provides additional capital to support growth initiatives Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a $40 million amended growth capital credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide. Under the amended facility, ...

Tuesday 1st August 2017

Cerus Announces Expanded Supply Agreement With

  Life Sciences Jobs   ...

Cerus Announces Expanded Supply Agreement with French National Blood Service

New contracts enable broad adoption of the INTERCEPT Blood System for platelets in France Cerus Corporation (NASDAQ: CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang (EFS), the French National Blood Service, for the INTERCEPT Blood System. One contract covers the supply of INTERCEPT Platelet kits w...

Thursday 27th July 2017

Cerus Corp CERS Medical Equipment Deals and Alliances Profile [Report Updated: 11072017] Prices from USD $250

SummaryCerus Corp Cerus is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusiontransmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for...

Cerus Announces Collaboration with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate

Strategic biologics initiative expands Cerus’ product portfolio. Cerus Corporation (NASDAQ:CERS) announced today an agreement with the Central California Blood Center (CCBC) in which CCBC will manufacture pathogen-reduced cryoprecipitate (“cryo”) for the company. Cryoprecipitate is a blood product derived from blood plasma and contains ...

Cerus Announces Collaboration with Central California Blood Center to Manufacture ...

Read more...

Wednesday 26th July 2017

Cerus Announces Collaboration With To Manufacture Pathogen-Reduced Cryoprecipitate

  Life Sciences Jobs   ...


Quick Search
Advertisement
 

News Quicklinks